Breaking News
January 16, 2018 - The Salk Institute and Indivumed collaborate for cutting-edge cancer research
January 16, 2018 - Study reveals negative long-term effects of heavy cannabis use on brain function and behavior
January 16, 2018 - Many gym-goers injure themselves by pushing harder to be better than friends
January 16, 2018 - Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
January 16, 2018 - Federal Junk Food Tax Feasible, Study Says
January 16, 2018 - Do girls have stronger teeth than boys?
January 16, 2018 - New high-sensitivity blood tests could aid faster diagnosis and treatment for heart attack
January 16, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
January 16, 2018 - Morning Break: Food Pharmacies; Obamacare Sign-ups Dip; Top Pot Studies
January 16, 2018 - Blood pressure declines 14 to 18 years before death
January 16, 2018 - Researchers use immune-mimicking biomaterial scaffolds to fast track T cell therapies
January 16, 2018 - Bile acids could directly burn away lipids in the fat depots
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Severe peer victimization in childhood may contribute to mental health issues in adolescence
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
January 16, 2018 - Dire view from within accident and emergency wards of England and Wales
January 16, 2018 - Study reveals how devastating mitochondrial diseases strike families without any previous history
January 16, 2018 - Experts look for ways to standardize treatments for pediatric rheumatic diseases
January 16, 2018 - Teens who watch TV shows with ads likely to eat more junk food
January 16, 2018 - Aztec apocalypse found to be Salmonella outbreak
January 16, 2018 - Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy
January 16, 2018 - Three Ineffective Institutional Approaches to Quality Improvement in Healthcare
January 16, 2018 - New technology accelerates autism diagnosis and treatment
January 16, 2018 - Preterm babies likely to experience delays in auditory brain development, study reveals
January 16, 2018 - Research sheds new light on genetic, environmental factors that promote prostate cancer metastasis
January 16, 2018 - Mitochondrial impairment may actually protect the brain in Parkinson’s disease, study shows
January 15, 2018 - Energy drinks can have adverse health effects on youth, study reveals
January 15, 2018 - 60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine
January 15, 2018 - Wanted: ‘Breathalyzer’ for Cannabis Use
January 15, 2018 - Surfers more likely to get antibiotic resistant E. coli in their guts
January 15, 2018 - “Baby brain” a real clinical entity finds study
January 15, 2018 - Whole of Britain to be put on a diet plan come March
January 15, 2018 - Neighborhood Deprivation Linked to Heart Failure
January 15, 2018 - Omega-3 and Omega-6 fatty acid intake may affect lupus outcomes
January 15, 2018 - Scientists discover new enzyme that could reduce obesity rates
January 15, 2018 - Evidence suggests two patterns of early symptoms precede and predict later BD risk
January 15, 2018 - Harm minimization approach for smoking cessation with e-cigarettes
January 15, 2018 - Surgery or Antibiotics for Appendicitis? Here’s What Patients Chose
January 15, 2018 - ASH: Frailty Screening Tool Guides Therapy in Elderly
January 15, 2018 - Study shows video games could cut dementia risk in seniors
January 15, 2018 - Common Food Additive Promoting C. diff?
January 15, 2018 - Mild traumatic brain injury causes long-term damage in mice
January 15, 2018 - Circadian clock proteins set the pace of plant growth
January 15, 2018 - Two proteins shown to regenerate brain in Parkinson’s disease
January 15, 2018 - Jotting down tasks may ease falling asleep, study says
January 15, 2018 - Chi-Med Initiates Fruquintinib U.S. Clinical Trials
January 15, 2018 - Cell-Free DNA May Help Pinpoint Breast Ca Survival
January 15, 2018 - What goes on inside a medically supervised injection facility?
January 15, 2018 - Research provides new model to better ascertain HIV mortality rates in Zambia
January 15, 2018 - Genetic analysis can enhance outcomes of depression treatment
January 15, 2018 - Variations in bacterial strains can trigger varying immune responses, study states
January 15, 2018 - TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
January 15, 2018 - HIV Vaccine Shows ‘Positive Signal’ in Small Study
January 15, 2018 - Researchers demonstrate RAS dimers are essential for cancer
January 15, 2018 - Groundbreaking report highlights plan to end bowel cancer
January 15, 2018 - Doc Aspires to Bring ‘Medicine the Musical’ to Off-Broadway
January 15, 2018 - Does an exploding brain network cause chronic pain?
January 15, 2018 - Researchers use novel PET tracer to assess myelin damage in mouse models of MS
January 15, 2018 - Survival strategy of mRNAs during sugar deficiency in the cell
January 15, 2018 - Hormone Therapy May Ease Depression Linked to Menopause
January 15, 2018 - Pain Sensitization Declines After Bariatric Tx in Obese Patients
January 15, 2018 - C7 nerve transfer improves function in spastic arm paralysis
January 15, 2018 - Australian kids are drinking and smoking far less than before
January 15, 2018 - Worsening of anxiety symptoms may be early indicator of Alzheimer’s disease
January 15, 2018 - Early testing for influenza symptoms can limit severe, life-threatening disease
Enzalutamide Safe In Seizure-Prone Prostate CA Patients

Enzalutamide Safe In Seizure-Prone Prostate CA Patients

image_pdfDownload PDFimage_print

Action Points

  • The androgen receptor inhibitor enzalutamide (Xtandi) did not raise seizure incidence when used at a dose of 160 mg/day in men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, in a multicenter, multinational trial.
  • Note that the data, along with the previously established efficacy profile, suggest that enzalutamide does not predispose to seizures and may be safely used in men with metastatic prostate cancer who have risk factors for seizure.

In men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, the androgen receptor inhibitor enzalutamide (Xtandi) didn’t raise seizure incidence when used at a dose of 160 mg/day, researchers found in a manufacturer-sponsored study.

Confirmed seizure incidence in the Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide (UPWARD) was 2.6 per 100 patient-years, according to Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues.

That’s about the same as the incidence previously calculated in a large retrospective analysis in the U.S., at 2.8 per 100 patient-years in patients with mCRPC and seizure risk factors who never took the drug, Slovin and colleagues reported online in JAMA Oncology.

“These data suggest that enzalutamide did not increase seizure incidence in men with mCRPC and seizure risk factors and is an option for patients with seizure risk factors,” the researchers wrote. “However, it should be used with caution and input from neurology specialists.”

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they added.

Jim Hu, MD, MPH, of New York Presbyterian/Weill Cornell Medicine in New York City, who wasn’t involved in the study, noted that the results contrast to those of a prior study, but they do suggest that “enzalutamide does not predispose to seizure. This demonstrates that enzalutamide may be safely used in men with metastatic prostate cancer who have risk factors for seizure.”

UPWARD was initiated following requests for additional safety information from the FDA and the European Medicines Agency. Although enzalutamide is known to prolong survival in men with mCRPC, phase I and II studies reported seizures in 3 of 140 (2%) enzalutamide-treated patients at doses greater than 360 mg/day.

Controlled clinical trials such as AFFIRM, PREVAIL, TERRAIN, and STRIVE have shown that with 160 mg of oral enzalutamide daily, only 0.5% of patients experienced seizure. However, patients with a history of seizure or risk factors were excluded from these trials, the researchers noted.

For UPWARD, they evaluated 423 patients at 73 sites in 20 countries, all of whom had at least one risk factor for seizure, including medications that lowered seizure threshold (57.2%); history of brain injury (26.5%); and history of cerebrovascular accident or transient ischemic attack (22.2%).

All patients received oral enzalutamide at a dose of 160 mg/day for an initial 4-month treatment period, and were given the option to extend treatment for one year.

Overall, 4 out of 366 evaluable patients (1.1%) had at least one confirmed seizure within 4 months of starting enzalutamide. The seizures were considered enzalutamide-related in 3 of the 4 patients. In addition, 3 patients (0.8%) had a seizure in the 4-month period after the study ended.

All 423 patients were included in the safety analysis. The majority (84.4%) experienced at least one treatment-emergent adverse event: 33.3% had at least one serious treatment-emergent adverse event, and 6.9% had at least one drug-related serious adverse event.

A total of 66 patients (15.6%) permanently discontinued treatment as a result of a drug-related AE, and three of these patients had a seizure, the researchers reported.

During the 4-month study period or within 30 days of the treatment ending, there were 38 deaths (9%), four of which were considered possibly drug-related. One patient died of cerebral hemorrhage, one of mCRPC progression, one experienced sudden cardiac death, and another had general deterioration. No seizure-related deaths were reported.

Study limitations included the fact that a randomized controlled trial wasn’t feasible, and that predisposing risk factors for seizure such as a history of seizure or of brain arteriovenous malformations were underrepresented, the researchers said.

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they concluded.

This study was funded by Astellas Pharma and Medivation (acquired by Pfizer in September 2016), the co-developers of enzalutamide. Both sponsors participated in the design and conduct of the study as well as analysis and interpretation of the data, approval of the manuscript, and decision to submit for publication. Lead author Slovin reported a relationship with Bayer AG. A number of co-authors also reported relationships with industry, including Astellas Pharma, Medivation, and Pfizer.


Tagged with:

About author

Related Articles